This Explains Horizon Pharma's 25% Plunge

Shares of Horizon Pharma PLC (NASDAQ: HZNP) plunged more than 25 percent on Tuesday after the company released an investor presentation which included revenue outlook.

Horizon Pharma said it expects its 2016 revenue to be in a range of $1.025 billion to $1.05 billion and adjusted EBITDA to be in a range of $505 million to $520 million.

Horizon Pharma's revenue guidance for the first quarter may be in a range of $195 million to $210 million (the company guided towards a 79 percent year-over-year growth at midpoint), falling short of the $228 million Wall Street analysts were expecting.

Shares traded recently at $13.60, down 25.4 percent.